In the validation cohort, however, the expression levels of RUFY3 were as expected in the DCIS and IBC classes (Supplementary Figure 9), especially when focusing the recurrent DCIS cases (Supplementary Figure 11). The gene discussed is RUFY3; the disease is ductal breast carcinoma in situ.